Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Trina Poretta

Voorhees, NJ Doctor of Osteopathy

NPI 1720082092 CMS profile 259419

705 White Horse Rd, Ste D105, Voorhees, NJ 08043

Open in the dashboard

General payments

$91,398

1,361 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Trina Poretta of Voorhees, NJ is reported in the CMS Open Payments database as having received $91,398 across 1,361 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,896 176
2024 General $3,832 185
2023 General $21,187 179
2022 General $27,062 201
2021 General $20,087 217
2020 General $11,351 176
2019 General $3,983 227

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Trina Poretta
  • New Jersey median
  • Middle half of New Jersey
  • National median

In program year 2025, general payments to Trina Poretta were reported at $3,896. Among 31,834 New Jersey profiles paid that year, the median was $178 and the middle half received between $51 and $585.

Show as a table
Year Trina Poretta New Jersey median Middle half National median
2019 $3,983 $150 $44–$542 $163
2020 $11,351 $110 $33–$349 $114
2021 $20,087 $125 $36–$419 $132
2022 $27,062 $142 $42–$480 $149
2023 $21,187 $156 $48–$510 $160
2024 $3,832 $167 $50–$562 $164
2025 $3,896 $178 $51–$585 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sobi, Inc $41,189 33 payments
  2. Dova Pharmaceuticals $24,441 18 payments
  3. Novartis Pharmaceuticals Corporation $2,421 95 payments
  4. E.R. Squibb & Sons, L.L.C. $1,860 88 payments
  5. Pfizer Inc. $1,452 88 payments
  6. Janssen Biotech, Inc. $1,329 63 payments
  7. AstraZeneca Pharmaceuticals LP $1,230 67 payments
  8. Incyte Corporation $982 54 payments
  9. Merck Sharp & Dohme Corporation $978 55 payments
  10. Gilead Sciences, Inc. $861 33 payments
  11. Other $14,657 767 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $61,710 18 payments
  2. Food and Beverage $24,562 1,296 payments
  3. Consulting Fee $2,250 1 payment
  4. Education $1,710 25 payments
  5. Gift $1,073 19 payments
  6. Travel and Lodging $93 2 payments
Products named General payments · program years 2019–2025
  1. Doptelet $65,418 43 payments
  2. KISQALI $1,503 47 payments
  3. OPDIVO $999 51 payments
  4. KEYTRUDA $931 52 payments
  5. Lenvima $652 45 payments
  6. IMBRUVICA Oncology $585 31 payments
  7. JAKAFI $576 38 payments
  8. Imbruvica Oncology $558 21 payments
  9. ENHERTU $543 25 payments
  10. CALQUENCE $531 23 payments
  11. Other $23,619 1,309 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

2,199

Median for Hematology-Oncology: 604

Drug cost

$9,776,409

Median for Hematology-Oncology: $1,306,514

Branded share of claims

57.9%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jakafi Ruxolitinib Phosphate Brand 42 $768,541
Ibrance Palbociclib Brand 45 $730,022
Imbruvica Ibrutinib Brand 55 $728,112
Revlimid Lenalidomide Brand 39 $709,716
Darzalex Faspro Daratumumab-Hyaluronidase-Fihj Brand 56 $610,437
Cabometyx Cabozantinib S-Malate Brand 30 $549,753
Calquence Acalabrutinib Maleate Brand 28 $423,242
Procrit Epoetin Alfa Brand 115 $395,415
Venclexta Venetoclax Brand 26 $377,545
Lenalidomide Generic 30 $364,398

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 115 billing codes

Paid by Medicare

$1,264,835

Of which drugs: $1,026,348

Medicare patients

636

Average age 75

Services billed

179,016

453 women, 183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Cancer 42%
Diabetes 39%
Chronic kidney disease 35%
Ischemic heart disease 33%
Atrial fibrillation 23%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 38 7,201 $148,839
Injection, ferric carboxymaltose, 1 mg J1439 Office 78 117,000 $102,281
Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 Office 17 3,483 $22,081
Injection, palonosetron hcl, 25 mcg J2469 Office 16 541 $378
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 42 3,457 $309
Injection, granisetron hydrochloride, 100 mcg J1626 Office 14 540 $142
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 34 116 $74

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 81 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
$324 — —
IMBRUVICA
$209 55 —
KEYTRUDA
$196 16 —
EPKINLY
$133 — —
LIBTAYO
$118 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 81 with Patron

Records

1,361 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record